{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:45:56Z","timestamp":1792007156574,"version":"4.4.0"},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gorlin-Goltz syndrome, also known as nevoid basal cell carcinoma syndrome or basal cell naevus syndrome, is a rare hereditary cancer-predisposition disorder most often caused by disruption of the Hedgehog signaling pathway, particularly alterations of\n                    <jats:italic>PTCH1<\/jats:italic>\n                    . Classical disease is characterized by multiple or early-onset basal cell carcinomas, odontogenic keratocysts, palmoplantar pits, skeletal anomalies and intracranial calcifications. Deletions involving chromosome region 9q22.3 may create an overlapping but broader phenotype because the deleted interval may include\n                    <jats:italic>PTCH1<\/jats:italic>\n                    together with neighboring genes.\n                  <\/jats:p>\n                  <jats:p>\n                    Hereby we report a 15-year-old female patient with developmental disability, including a specific speech articulation disorder, who presented with multiple facial erosions, scars, milia, papulo-nodular lesions and palmar pitting. Dermoscopy demonstrated arborizing vessels, blue-gray ovoid nests, brown dots, ulceration, white scales and shiny white perpendicular lines. Surgical excision of selected lesions was performed, and histopathology confirmed basal cell carcinoma in three specimens, reported as carcinoma basocellulare. Additional findings included a nasal-root dermoid cyst excised in early childhood, strabismus, conductive hearing loss, kyphoscoliosis and a kinked aorta. Multiplex ligation-dependent probe amplification (MLPA) using the SALSA MLPA Probemix P245-A2 Microdeletion Syndromes-1 (MRC-Holland, Amsterdam, The Netherlands) demonstrated a deletion involving the\n                    <jats:italic>PTCH1<\/jats:italic>\n                    region at chromosome 9q22.3.\n                  <\/jats:p>\n                  <jats:p>\n                    This case is highly suggestive of a\n                    <jats:italic>PTCH1<\/jats:italic>\n                    -region deletion presenting with a Gorlin-Goltz phenotype, with additional extracutaneous findings that may reflect involvement of the wider 9q22.3 region; because MLPA cannot delineate deletion boundaries or confirm loss of neighboring genes, this broader interpretation remains presumptive pending array-based confirmation. The occurrence of multiple basal cell carcinomas in adolescence should prompt evaluation for inherited tumor-predisposition syndromes. When extracutaneous developmental or congenital abnormalities are present, genetic testing capable of detecting and mapping copy-number variants should be considered.\n                  <\/jats:p>","DOI":"10.2478\/bjmg-2026-0013","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:57:25Z","timestamp":1792004245000},"page":"55-62","source":"Crossref","is-referenced-by-count":0,"title":["Multiple Basal Cell Carcinomas in an Adolescent with an MLPA-Detected\n                    <i>PTCH1<\/i>\n                    -Region Deletion and a Gorlin-Goltz Phenotype"],"prefix":"10.2478","volume":"29","author":[{"given":"J","family":"Mitrova Telenta","sequence":"first","affiliation":[{"name":"University Clinic of Dermatology , Faculty of Medicine, \u201cSs. Cyril and Methodius\u201d University , Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Risteska","sequence":"additional","affiliation":[{"name":"University Clinic of Dermatology , Faculty of Medicine, \u201cSs. Cyril and Methodius\u201d University , Skopje , R. N. Macedonia"},{"name":"PHI General Hospital Ohrid , Ohrid , R.N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Dohcheva Karajovanov","sequence":"additional","affiliation":[{"name":"University Clinic of Dermatology , Faculty of Medicine, \u201cSs. Cyril and Methodius\u201d University , Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Breshkovska","sequence":"additional","affiliation":[{"name":"University Clinic of Dermatology , Faculty of Medicine, \u201cSs. Cyril and Methodius\u201d University , Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Duma","sequence":"additional","affiliation":[{"name":"University Clinic of Dermatology , Faculty of Medicine, \u201cSs. Cyril and Methodius\u201d University , Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Mircevska Arsovska","sequence":"additional","affiliation":[{"name":"University Clinic of Dermatology , Faculty of Medicine, \u201cSs. Cyril and Methodius\u201d University , Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Dimova","sequence":"additional","affiliation":[{"name":"University Clinic of Dermatology , Faculty of Medicine, \u201cSs. Cyril and Methodius\u201d University , Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Simeonovski","sequence":"additional","affiliation":[{"name":"University Clinic of Dermatology , Faculty of Medicine, \u201cSs. Cyril and Methodius\u201d University , Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Plaseska-Karanfilsk\u0430","sequence":"additional","affiliation":[{"name":"Research Center for Genetics Engineering and Biotechnology\u201d Georgi Efremov\u201d, Macedonian Academy of Sciences and Arts , Skopje , R.N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Ahtarova","sequence":"additional","affiliation":[{"name":"Primaderma-private practice , Strumica , R.N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"2026101418572414114_j_bjmg-2026-0013_ref_001","doi-asserted-by":"crossref","unstructured":"Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib: a syndrome. N Engl J Med. 1960;262:908\u2013912. doi:10.1056\/NEJM196005052621803.","DOI":"10.1056\/NEJM196005052621803"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_002","doi-asserted-by":"crossref","unstructured":"Evans DGR, Ladusans EJ, Rimmer S, Burnell LD, Thakker N, Farndon PA. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet. 1993;30(6):460\u2013464. doi:10.1136\/jmg.30.6.460.","DOI":"10.1136\/jmg.30.6.460"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_003","doi-asserted-by":"crossref","unstructured":"Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, DiGiovanna JJ, Bale AE, Bale SJ. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997;69(3):299\u2013308.","DOI":"10.1002\/(SICI)1096-8628(19970331)69:3<299::AID-AJMG16>3.0.CO;2-M"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_004","doi-asserted-by":"crossref","unstructured":"Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med. 2004;6(6):530\u2013539. doi:10.1097\/01.gim.0000144188.15902.c4.","DOI":"10.1097\/01.GIM.0000144188.15902.C4"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_005","doi-asserted-by":"crossref","unstructured":"Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis. 2008;3:32. doi:10.1186\/1750-1172-3-32.","DOI":"10.1186\/1750-1172-3-32"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_006","doi-asserted-by":"crossref","unstructured":"Bree AF, Shah MR; BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am J Med Genet A. 2011;155A(9):2091\u20132097. doi:10.1002\/ajmg.a.34128.","DOI":"10.1002\/ajmg.a.34128"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_007","doi-asserted-by":"crossref","unstructured":"Verkouteren BJA, Cosgun B, Reinders MGHC, Kessler PAWK, Vermeulen RJ, Klaassens M, Lambrechts S, van Rheenen JR, van Geel M, Vreeburg M, Mosterd K. A guideline for the clinical management of basal cell naevus syndrome (Gorlin-Goltz syndrome). Br J Dermatol. 2022;186(2):215\u2013226. doi:10.1111\/bjd.20700.","DOI":"10.1111\/bjd.20700"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_008","doi-asserted-by":"crossref","unstructured":"Jones EA, Sajid MI, Shenton A, Evans DG. Basal cell carcinomas in Gorlin syndrome: a review of 202 patients. J Skin Cancer. 2011;2011:217378. doi:10.1155\/2011\/217378","DOI":"10.1155\/2011\/217378"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_009","unstructured":"Evans DG. Nevoid Basal Cell Carcinoma Syndrome. In: Adam MP, Feldman J, Mirzaa GM, et al, editors. GeneReviews. Seattle: University of Washington, Seattle; updated 2024."},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_010","unstructured":"Spiker AM, Troxell T, Ramsey ML. Gorlin Syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024."},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_011","doi-asserted-by":"crossref","unstructured":"Smith MJ, Beetz C, Williams SG, Bhaskar SS, O\u2019Sullivan J, Anderson B, Daly SB, Urquhart JE, Bholah Z, Oudit D, Cheesman E, Kelsey A, McCabe MG, Newman WG, Evans DG. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol. 2014;32(36):4155\u20134161. doi:10.1200\/JCO.2014.58.2569.","DOI":"10.1200\/JCO.2014.58.2569"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_012","doi-asserted-by":"crossref","unstructured":"Muller EA, Aradhya S, Atkin JF, Carmany EP, Elliott AM, Chudley AE, Clark RD, Everman DB, Garner S, Hall BD, Herman GE, Kivuva E, Ramanathan S, Stevenson DA, Stockton DW, Hudgins L. Microdeletion 9q22.3 syndrome includes metopic craniosynostosis, hydrocephalus, macrosomia, and developmental delay. Am J Med Genet A. 2012;158A(2):391\u2013399. doi:10.1002\/ajmg.a.34216.","DOI":"10.1002\/ajmg.a.34216"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_013","doi-asserted-by":"crossref","unstructured":"Shimojima K, Adachi M, Tanaka M, Tanaka Y, Kurosawa K, Yamamoto T. Clinical features of micro-deletion 9q22.3. Clin Genet. 2009;75(4):384\u2013393. doi:10.1111\/j.1399-0004.2008.01141.x.","DOI":"10.1111\/j.1399-0004.2008.01141.x"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_014","doi-asserted-by":"crossref","unstructured":"Yamamoto K, Yoshihashi H, Furuya N, Adachi M, Ito S, Tanaka Y, Masuno M, Chiyo H, Kurosawa K. Further delineation of 9q22 deletion syndrome associated with basal cell nevus (Gorlin) syndrome: report of two cases and review of the literature. Congenit Anom (Kyoto). 2009;49(1):8\u201314. doi:10.1111\/j.1741-4520.2008.00210.x.","DOI":"10.1111\/j.1741-4520.2008.00212.x"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_015","unstructured":"de Ravel TJL, Balikova I, Thienpont B, Hannes F, Maas N, Fryns JP, et al. Early detection of chromo-some 9q22.32q31.1 microdeletion including the PTCH1 gene. Eur J Med Genet. 2009;52(5):270\u2013273."},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_016","doi-asserted-by":"crossref","unstructured":"Musani V, Ozretic P, Sabol M, Levanat S. Gorlin syndrome patient with large deletion in 9q22.32\u2013q22.33 detected by array-CGH. Clin Genet. 2009;76(3):308\u2013309.","DOI":"10.1159\/000219247"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_017","doi-asserted-by":"crossref","unstructured":"Isidor B, Bourdeaut F, Lafon D, Plessis G, Lacaze E, Kannengiesser C, Rossignol S, Pichon O, Briand A, Martin-Coignard D, Piccione M, David A, Delattre O, Jeanpierre C, Sevenet N, Le Caignec C. Wilms\u2019 tumor in patients with 9q22.3 microdeletion syndrome suggests a role for PTCH1 in nephroblastomas. Eur J Hum Genet. 2013;21(7):784\u2013787. doi:10.1038\/ejhg.2012.252.","DOI":"10.1038\/ejhg.2012.252"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_018","doi-asserted-by":"crossref","unstructured":"Garavelli L, Piemontese MR, Cavazza A, Rosato S, Wischmeijer A, Gelmini C, Albertini E, Albertini G, Forzano F, Franchi F, Carella M, Zelante L, Superti-Furga A. Multiple tumor types including leio my oma and Wilms tumor in a patient with Gorlin syn dro me due to 9q22.3 microdeletion encompassing the PTCH1 and FANCC loci. Am J Med Genet A. 2013;161A(11):2894\u20132901. doi:10.1002\/ajmg.a.36259.","DOI":"10.1002\/ajmg.a.36259"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_019","doi-asserted-by":"crossref","unstructured":"Cayrol J, et al. Wilms tumor associated with the 9q22.3 microdeletion syndrome: two new case reports and review of the literature. J Pediatr Hematol Oncol. 2019;41(1):e13\u2013e17.","DOI":"10.1097\/MPH.0000000000001322"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_020","doi-asserted-by":"crossref","unstructured":"Yamada H, Shimura M, Takahashi H, Nara S, Morishi ma Y, Go S, Miyashita T, Numabe H, Kawashima H. A familial case of overgrowth syndrome caused by a 9q22.3 microdeletion in a mother and daughter. Eur J Med Genet. 2020;63(5):103872. doi:10.1016\/j.ejmg.2020.103872.","DOI":"10.1016\/j.ejmg.2020.103872"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_021","doi-asserted-by":"crossref","unstructured":"Ewing AD, Ellard S, Pollard MO, Baker K. Microdeletion of 9q22.3: a patient with minimal deletion removing PTCH1. Am J Med Genet A. 2021;185(7):2216\u20132220. doi:10.1002\/ajmg.a.62224.","DOI":"10.1002\/ajmg.a.62224"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_022","doi-asserted-by":"crossref","unstructured":"Kieny A, Kremer V, Scheidecker S, Lipsker D. 9q22.3 microdeletion syndrome with multiple basal cell carcinomas treated with vismodegib: three key messages in one patient. Acta Derm Venereol. 2018;98(2):287\u2013288. doi:10.2340\/00015555-2822.","DOI":"10.2340\/00015555-2822"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_023","doi-asserted-by":"crossref","unstructured":"Reiter O, Mimouni I, Dusza S, Halpern AC, Leshem YA, Marghoob AA. Dermoscopic features of basal cell carcinoma and its subtypes: a systematic review. J Am Acad Dermatol. 2021;85(3):653\u2013664.","DOI":"10.1016\/j.jaad.2019.11.008"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_024","doi-asserted-by":"crossref","unstructured":"Lallas A, Apalla Z, Argenziano G, Longo C, Moscarella E, Specchio F, et al. The dermatoscopic universe of basal cell carcinoma. Dermatol Pract Concept. 2014;4(3):11\u201324. doi:10.5826\/dpc.0403a02.","DOI":"10.5826\/dpc.0403a02"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_025","doi-asserted-by":"crossref","unstructured":"Ungureanu L, Cosgarea R, Senila S, Rogojan L. Role of dermoscopy in the assessment of basal cell carcinoma. Front Med (Lausanne). 2021;8:718855. doi:10.3389\/fmed.2021.718855.","DOI":"10.3389\/fmed.2021.718855"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_026","unstructured":"Wojtowicz I, et al. Dermoscopy of basal cell carcinoma, Part 1: dermoscopic criteria and differential diagnosis. Dermatol Pract Concept. 2025;15:e2025000."},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_027","doi-asserted-by":"crossref","unstructured":"Booms P, Harth M, Sader R, Ghanaati S. Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas in Gorlin-Goltz syndrome. J Craniomaxillofac Surg. 2015;43(6):1021\u20131025. doi:10.1016\/j.jcms.2015.03.020.","DOI":"10.1016\/j.jcms.2015.03.020"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_028","doi-asserted-by":"crossref","unstructured":"Verkouteren BJA, Wakkee M, Mosterd K, Mooyaart AL. Update on Hedgehog pathway inhibitor therapy for patients with basal cell naevus syndrome or high-frequency basal cell carcinoma. Acta Derm Venereol. 2022;102:adv00704.","DOI":"10.2340\/actadv.v102.980"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_029","doi-asserted-by":"crossref","unstructured":"Palmeiro AG, et al. Vismodegib in Gorlin-Goltz syndrome: a systematic review. Dermatol Ther (Heidelb). 2024;14:1547\u20131564.","DOI":"10.1111\/ajd.14326"},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_030","unstructured":"Ojevwe FO, et al. Treatment of multiple unresectable basal cell carcinomas in Gorlin-Goltz syndrome with vismodegib. J Drugs Dermatol. 2015;14(4):423\u2013426."},{"key":"2026101418572414114_j_bjmg-2026-0013_ref_031","doi-asserted-by":"crossref","unstructured":"Piccerillo A, Patrizi A, Mandel VD, Baraldi C, Savoia F, Misciali C, et al. Sonidegib after vismodegib discontinuation in a patient with Gorlin-Goltz syndrome. Dermatol Ther. 2021;34(4):e15030.","DOI":"10.1111\/dth.15095"}],"container-title":["Balkan Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/bjmg-2026-0013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:57:30Z","timestamp":1792004250000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/bjmg-2026-0013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,10,14]]},"published-print":{"date-parts":[[2026,7,1]]}},"alternative-id":["10.2478\/bjmg-2026-0013"],"URL":"https:\/\/doi.org\/10.2478\/bjmg-2026-0013","relation":{},"ISSN":["2199-5761"],"issn-type":[{"value":"2199-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}